Three years ago, the United States was recording more than 110,000 drug overdose deaths per year — a number that seemed impossible to reverse. It is being reversed.
Preliminary CDC data released June 17, 2026 show approximately 69,147 drug overdose deaths in the 12 months ending January 2026, a 13.2 percent decline compared to the previous year. It is the third consecutive year of significant decline, following drops of approximately 27 percent from 2023 to 2024 and an earlier decline from the peak.
The progress is real. It is also fragile. And a new threat — a veterinary sedative called medetomidine spreading through the illicit fentanyl supply — could directly undermine the tools that have been driving the gains.
Why This Matters
The overdose crisis has killed more than 1 million Americans since 1999. The recent declines represent the clearest evidence yet that evidence-based public health interventions can bend this curve even against a highly lethal drug supply. That is worth documenting and understanding clearly.
But the same organizations that are celebrating the progress are warning loudest about its fragility. Shatterproof, one of the leading addiction advocacy organizations, noted in May 2026: "Nearly 70,000 lives lost to overdose in 2025 remains a public health crisis of staggering scale. What is being called progress today would have been considered a national emergency just a few years ago."
What We Know So Far
The decline from the 2023 peak of more than 110,000 deaths has happened rapidly — roughly 37 percent in two years. Experts have offered multiple theories for what drove the initial and sustained drops, including the increased availability of naloxone (the opioid overdose reversal medication), expanded access to buprenorphine (an evidence-based medication for opioid use disorder), the growing impact of multibillion-dollar opioid lawsuit settlements that funded treatment and prevention infrastructure, and possible supply-side disruptions to fentanyl precursor chemicals.
The American Medical Association's 2025 overdose report credited multiple converging factors: "widespread, data-driven distribution of naloxone; better access to evidence-based treatment for substance use disorders; shifts in the illegal drug supply; a resumption of prevention and response after pandemic-related disruptions; and continued investments in prevention and response programs."
The AMA also reported that nearly 2 million naloxone prescriptions were dispensed in 2024, and buprenorphine prescriptions have increased 83 percent over the past decade.
What Is Working
Researchers have identified several interventions with the strongest evidence base for the declines:
Naloxone access expansion. Making naloxone available over the counter, through pharmacies, community health workers, and harm reduction programs, has put the reversal agent in the hands of people who can use it at the moment of overdose.
Buprenorphine access. The removal of the X-waiver requirement that had long restricted which physicians could prescribe buprenorphine opened treatment to more providers in more settings. Buprenorphine dramatically reduces the risk of overdose death among people with opioid use disorder.
Harm reduction infrastructure. Fentanyl test strips, supervised consumption services in some jurisdictions, and expanded outreach in communities hardest hit by overdose deaths have all contributed.
Supply-side shifts. Changes in fentanyl potency and purity appear to have played a role, though researchers debate the relative contribution.
What Could Reverse the Gains
The most immediate and documented threat to the decline is medetomidine — the veterinary sedative now being detected at sharply rising rates in the illicit fentanyl supply, particularly in the Northeast and Midwest.
Medetomidine cannot be reversed by naloxone. When someone overdoses on fentanyl mixed with medetomidine, administering naloxone will address the opioid component — but the medetomidine will continue to cause dangerous sedation, low blood pressure, and slow heart rate. Emergency medical care beyond naloxone is essential.
New York City data show medetomidine contributed to 134 fatal overdoses in 2025, up from 18 in 2024 — a sevenfold increase in a single year. Nationally, detections in forensic lab reports rose from 247 in 2023 to 8,233 in 2025.
Beyond medetomidine, Shatterproof has warned that the evolving drug supply now includes other emerging synthetic substances — nitazenes, cychlorphine, and other compounds — whose effects may also not respond fully to naloxone or existing treatments.
The Policy Threat
Significant cuts to federal health programs also threaten to undermine the infrastructure that has driven the decline. The Medicaid cuts enacted in the One Big Beautiful Bill Act of 2025 are projected to remove millions of Americans from health coverage, including many with opioid use disorder who access treatment through Medicaid. Buprenorphine, methadone, and behavioral health services are all Medicaid-covered benefits that become inaccessible without insurance.
Shatterproof stated explicitly: "Now is not the time to scale back. We need continued investment in prevention, early intervention, quality treatment access, recovery supports, harm reduction services, workforce development, and policies that address the stigma surrounding substance use disorder."
Who Faces the Greatest Risk?
The populations most affected by the ongoing overdose crisis — even as overall numbers have declined — include:
- People with opioid use disorder who lack access to medications like buprenorphine or methadone
- Residents of communities where medetomidine has been detected in the drug supply
- People who may have lost Medicaid coverage and, therefore, lost access to treatment
- Communities where naloxone is not yet widely distributed or accessible
- Rural residents far from emergency medical care
Some states continue to see overdose death increases even as the national average declines, reflecting the uneven distribution of both the crisis and the interventions.
What You Can Do Now
- If you or someone you know has an opioid use disorder, seek evidence-based treatment. Buprenorphine and methadone are the most effective medications and can be obtained through primary care providers, addiction specialists, and opioid treatment programs.
- Carry naloxone — it is still essential. But understand that naloxone alone may not be sufficient if medetomidine is present. Always call 911 immediately after administering naloxone.
- If you live in a high-risk community, contact your local health department or harm reduction program about fentanyl and medetomidine test strips.
- Verify that your health insurance covers addiction treatment services. If you are on Medicaid, check whether any coverage changes affect your access to buprenorphine.
- Support local and federal funding for overdose prevention, harm reduction, and treatment infrastructure.
Cost and Access: What Patients Should Know
Naloxone is available over the counter without a prescription and is covered by most insurance plans. The SAMHSA National Helpline (1-800-662-4357) provides free, confidential information and treatment referrals 24/7.
For people without insurance, federally qualified health centers and Opioid Treatment Programs are required to accept patients regardless of ability to pay and must offer medications for opioid use disorder.
What Happens Next
Final 2025 overdose death data will be released by the CDC in the coming months, which may revise the preliminary estimate upward or downward. The CDC's Overdose Data to Action program will continue monitoring medetomidine and other emerging substances. Shatterproof and other advocacy organizations have called for sustained federal investment in prevention and treatment infrastructure through 2026 and beyond.
The Bottom Line
Three consecutive years of declining overdose deaths represent real progress — saved lives and working interventions. But the crisis is far from over, and the emergence of medetomidine in the fentanyl supply is a direct threat to what has been working. Maintaining the gains will require sustained investment in naloxone access, treatment expansion, harm reduction infrastructure, and surveillance for new substances. Now is not the moment to assume the problem is solved.
References
- CDC — Drug Overdose Data Resources (June 17, 2026 update)
- Shatterproof — Statement Regarding the Just-Released 2025 CDC Overdose Numbers
- AMA — 2025 Report on Substance Use and Treatment
- CDC — Medetomidine Situation Summary
- CDC — CDC Reports Decline in U.S. Drug Overdose Deaths (2024 report)
- Washington Examiner — Overdose Deaths Fell to Pre-Pandemic Levels in 2025
